Jaguar Animal Health Inc. ( (JAGX) ) has released its Q3 earnings. Here is a breakdown of the information Jaguar Animal Health Inc. presented ...

Quiterio Ramírez’s voice is heavy with anguish at the other end of the phone: “When I saw the jaguar hanging there, the truth ...

Jaguar Health announced that its product, cofelemer delayed-release tablets (Canalevia-CA1; Jaguar Health), received approved ...

Colombia is home to some 16,000 jaguars, but their habitat is becoming increasingly fragmented. A new initiative seeks to ...

JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced that the U.S. Food and Drug Administration (FDA) has approved renewal of Canalevia-CA1 (crofelemer ...

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, ...

CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA ...

increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 ...